Read + Share
. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first
line treatment in patients with HER2 positive metastatic breast cancer (PHILA):
randomised, double blind, multicentre, phase 3 trial. BMJ 2023;383:p2665.
PMID: 37973164
|
 |
|
